课题基金 / 基金详情

Vanderbilt Hypertension and Blood Pressure Regulation Program

Vanderbilt Hypertension and Blood Pressure Regulation Program
范德比尔特高血压和血压调节计划
批准号:
10597621
负责人:
David G Harrison
金额:
$38.26万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
未结题
起止时间:
2019-02-01 至 2025-01-31

项目摘要

项目成果

David G Harrison的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT This is a new program to train the next generation of scientists in the fields of hypertension and blood pressure regulation. These conditions represent enormous health care problems. The new American Heart Association and American College of Cardiology Guidelines now classify almost 50% of the adult population as being hypertensive. Autonomic dysfunction, manifested by syncope, presyncope and postural intolerance, becomes increasingly common with age and is terribly disabling. Despite the commonality of these disorders, their precise etiology remains poorly defined. Moreover, they often associated with and share underlying mechanisms with other cardiovascular and metabolic disorders. It is therefore mandatory that we train and develop outstanding scientists to pursue these related areas of investigation. We propose to ultimately include 4 post-doctoral fellows and 2 predoctoral graduate students in Vanderbilt Hypertension and Blood Pressure Regulation (VHBPR) program. These trainees will be involved in three related facets of research. One has to do with understanding mechanisms of hypertension and end organ damage and the role inflammation and immune activation. Members of the VHBPR have led the field in defining mechanisms of immune activation in hypertension and related fields and this has evolved into a new understanding of the vascular, renal and cerebral dysfunction and damage that occurs in this and associated cardiovascular illnesses. Trainees involved in these programs will become familiar with an emerging area of immunology as it pertains to hypertension and cardiovascular diseases. The second important area of investigation is conducted by our Vanderbilt Autonomic Dysfunction Center. This center performs translational research involving laboratory, animal and clinical research. A third major area of investigation relates to bioinformatics of hypertension and drug responses. These studies are greatly facilitated by the BioVu database (the Vanderbilt DNA database) that contains DNA for >300,000 patients and the Synthetic derivative (de-identified medical records linked to BioVu) and are facilitated by our Division of Genetic Medicine and Center for Personalized Medicine. Our trainees will have the opportunity to initiate studies on medication-resistant hypertension, as more than 15,000 BioVU subjects with documented medication-resistant hypertension will have genome interrogation completed by 2018, including a large number of African American subjects. In addition to these laboratory research experiences, the VHBPR program includes seminars, didactic lectures and specialized course work devoted to career development, leadership, responsible conduct of research and work life balance. In addition to this core curriculum, trainees in specialized areas will participate in tailored coursework and workshops related to their specific areas of investigation. The ultimate goal is to train successful scientists that will successfully compete for future funding and who can pursue successful academic careers.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
Common Inflammation Pathways between Aging and Hypertension That Weaken Bone
Common Inflammation Pathways between Aging and Hypertension That Weaken Bone
Vanderbilt Hypertension and Blood Pressure Regulation Program
  • 批准号:
    10385839
  • 项目类别:
  • 资助金额:
    $41.45万
  • 财政年份:
    2019
  • 负责人:
    David G Harrison
  • 依托单位:
Mechanisms of Immune Activation in Hypertension
海外基金